Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has greatly improved
the clinical efficacy of malignant tumor therapy. ICI-mediated antitumor responses depend …

The tumor microenvironment (TME) is connected to immunotherapy responses, but it
remains unclear how cancer cells and host tissues differentially influence the immune …

Infiltration of regulatory T (Treg) cells, an immunosuppressive population of CD4+ T cells,
into solid cancers represents a barrier to cancer immunotherapy. Chemokine receptors are …

Tumor microenvironments (TMEs) influence cancer progression but are complex and often
differ between patients. Considering that microenvironment variations may reveal rules …

Intratumoral immune cells are crucial for tumor control and antitumor responses during
immunotherapy. Immune cell trafficking into tumors is mediated by binding of specific …

Tumors are populated by antigen-presenting cells (APCs) including macrophage subsets
with distinct origins and functions. Here, we examined how cancer impacts mononuclear …

Developing strategies to inflame tumors is critical for increasing response to immunotherapy.
Here, we report that low-dose radiotherapy (LDRT) of murine tumors promotes T-cell …

A paradigm shift in the understanding of the exhausted CD8+ T cell (Tex) lineage is
underway. Originally thought to be a uniform population that progressively loses effector …

Background An in-depth understanding of immune evasion mechanisms in tumors is crucial
to overcome resistance and enable innovative advances in immunotherapy. Circular RNAs …